Literature DB >> 15585987

Soluble CD40 ligand is an early initiator of inflammation after coronary intervention.

Atul Aggarwal1, Arnon Blum, David J Schneider, Burton E Sobel, Harold L Dauerman.   

Abstract

BACKGROUND: This prospective study evaluated the early increase in markers of inflammation after coronary stenting, and the predictors of early rise. Elevation of markers of inflammation after percutaneous coronary intervention correlates with an increased risk of adverse events. The role of soluble CD40 ligand (sCD40L) as a potential initiator of inflammation after stenting has not been described.
METHODS: Seventy-five patients were treated with heparin alone (n=25), or randomized to adjuvant treatment with eptifibatide (n=26) or abciximab (n=24) during stenting. Systemic blood was obtained before coronary stenting and at 10 min after stenting. C-reactive protein (CRP), interleukin (IL)-6, IL-1 receptor antagonist and sCD40L were determined by enzyme liberated immunosorbent assay.
RESULTS: sCD40L exhibited the greatest relative rise (35%, P=0.01 compared to concentrations before intervention) in the first 10 min after stenting. In a logistic regression model, an early increase in the concentration of sCD40L was predicted by baseline laboratory values (white blood count and sCD40L level before stenting) and procedural characteristics (number of stents and glycoprotein IIb-IIIa inhibitor assignment).
CONCLUSIONS: In conclusion, a systemic inflammatory response is detectable 10 min after coronary stent placement. The early increase in sCD40L suggests a possible role for this marker in the initiation of inflammation after coronary stenting.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585987     DOI: 10.1097/00019501-200412000-00003

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  11 in total

1.  Blockade of CD40 ligand for intercellular communication reduces hypertension, placental oxidative stress, and AT1-AA in response to adoptive transfer of CD4+ T lymphocytes from RUPP rats.

Authors:  Denise C Cornelius; Javier Castillo; Justin Porter; Lorena M Amaral; Nathan Campbell; Adrienne Paige; Alexia J Thomas; Ashlyn Harmon; Mark W Cunningham; Kedra Wallace; Florian Herse; Gerd Wallukat; Ralf Dechend; Babbette LaMarca
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-08-26       Impact factor: 3.619

2.  CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury.

Authors:  Guohong Li; John M Sanders; Melissa H Bevard; Zhiqi Sun; James W Chumley; Elena V Galkina; Klaus Ley; Ian J Sarembock
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

3.  Circulating soluble CD40 ligand mediates the interaction between neutrophils and platelets in acute coronary syndrome.

Authors:  Budi Y Setianto; Anggoro B Hartopo; Putrika P R Gharini; Dyah W Anggrahini; Bambang Irawan
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

4.  Increased local cytokine production at culprit superficial femoral artery plaques.

Authors:  Cameron W Donaldson; David J Schneider; Daniel J Bertges; Julie E Adams; Nader Z Elgharib; Enkhtuyaa L Mueller; William Prabhu; Taka Ashikaga; Harold L Dauerman
Journal:  J Thromb Thrombolysis       Date:  2013-10       Impact factor: 2.300

5.  Predictors of external cooling failure after cardiac arrest.

Authors:  Sylvie Ricome; Florence Dumas; Nicolas Mongardon; Olivier Varenne; Jérôme Fichet; Frédéric Pène; Benjamin Zuber; Benoît Vivien; Julien Charpentier; Jean-Daniel Chiche; Jean-Paul Mira; Alain Cariou
Journal:  Intensive Care Med       Date:  2013-01-08       Impact factor: 17.440

Review 6.  Impact of C-reactive protein on in-stent restenosis: a meta-analysis.

Authors:  Jian-Jun Li; Yi Ren; Ke-Ji Chen; Alan C Yeung; Bo Xu; Xin-Min Ruan; Yue-Jin Yang; Ji-Lin Chen; Run-Lin Gao
Journal:  Tex Heart Inst J       Date:  2010

7.  Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel.

Authors:  Shokoufeh Hajsadeghi; Mandana Chitsazan; Mitra Chitsazan; Negar Salehi; Ahmad Amin; Arash Amin Bidokhti; Nima Babaali; Armin Bordbar; Maral Hejrati; Samar Moghadami
Journal:  Clin Med Insights Cardiol       Date:  2016-08-29

Review 8.  Influence of Cardiometabolic Risk Factors on Platelet Function.

Authors:  Cristina Barale; Isabella Russo
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

9.  Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study.

Authors:  Joanna J Wykrzykowska; Ascan Warnholtz; Peter de Jaeger; Nick Curzen; Keith G Oldroyd; Jean Philippe Collet; Jurrien M Ten Berg; Tessa Rademaker; Dick Goedhart; Jurgen Lissens; Peter-Paul Kint; Patrick W Serruys
Journal:  J Thromb Thrombolysis       Date:  2009-11       Impact factor: 2.300

10.  Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, controlled study.

Authors:  Boris Schnorbus; Andreas Daiber; Kerstin Jurk; Silke Warnke; Jochem König; Ulrike Krahn; Karl Lackner; Thomas Munzel; Tommaso Gori
Journal:  BMJ Open       Date:  2014-05-06       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.